Hamilton G, Rath B. Smoking, inflammation and small cell lung cancer: recent developments. Wien Medizinische Wochenschr. 2015;165:379–86. https://doi.org/10.1007/s10354-015-0381-6.
Google Scholar
Lesko SM, Rosenberg L, Kaufman DW, Helmrich SP, Miller DR, Strom B, et al. Cigarette smoking and the risk of endometrial cancer. N Engl J Med. 1985;313:593–6. https://doi.org/10.1056/nejm198509053131001.
Google Scholar
Rohrmann S, Linseisen J, Allen N, Bueno-de-mesquita H, Johnsen N, Tjønneland A, et al. Smoking and the risk of prostate cnacer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer. 2013;108:708–14.
Google Scholar
Ordonez-Mena JM, Schottker B, Mons U, Jenab M, Freisling H, Bueo-de-Mesquita B, et al. Quantification of the smoking-associted cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium. BMC Med. 2016;14:62.
Watters JL, Park Y, Hollenbeck A, Schatzkin A, Albanes DE, et al. Cigarette smoking and prostate cancer in prospective US cohort study. Cancer Epidemiol Biomark Prev. 2009;18:2427–35.
Google Scholar
Moreira DM, Aronson WJ, Terris MK, Kane C, Amling C, Cooperberg M, et al. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy. Cancer. 2013;120:197–204.
Foerster B, Pozo C, Abufaraj M, Mari A, Kimura S, D’Andrea D, et al. Association of smoking status with recurrence, metastasis, and mortality among patients with localized prostate cancer undergoing prostatectomy or radiotherapy: a systematic review and meta-analysis. JAMA Oncol. 2018;4:953–61.
Kenfield SA, Stampfer MJ, Chan JM, et al. Smoking and prostate cancer survival and recurrence. JAMA. 2011;305:2548–55.
Google Scholar
Shui IM, Wong CJ, Zhao S, Kolb S, Ebot E, Geybels M, et al. Prostate tumor DNA methylation is associated with cigarette smoking and averse prostate cancer outcomes. Cancer. 2016;122:2168–77.
Google Scholar
George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524:47–53.
Google Scholar
Rudin CM, Durinck S, Stawiski EW, Poirier J, Modrusan Z, Shames D, et al. Comprehensive genomic analysis identifies SOX2 as frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44:1111–6.
Google Scholar
Su S, Zou JJ, Zeng YY, Cen WC, Zhou W, Liu Y, et al. Tumor mutational burden and genomic alterations in Chinese small cell lung cancer measure by whole-exome sequencing. Biomed Res Int. 2019;2019:6096350.
Oh MS, Garon E, Lisberg A, Cummings A, Barett A, Ashok A, et al. Brief report: the genomic landscape of small cell lung cancer in never-smoking patients. Clin Lung Cancer. 2025;26:434–9. https://doi.org/10.1016/j.cllc.2025.03.011.
Chen R, Dong X, Gleave M. Molecular model for neuroendocrine prostate cancer progression. BJUI. 2018;122:560–70.
Hubbard GK, Mutton LN, Khalili M, McMullin RP, Hicks JL, Bianchi-Frias D, et al. Combined MYC activation and Pten loss are sufficient to create genomic instability and lethal metastatic prostate cancer. Cancer Res. 2015;76:8–11.
Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1:487–95.
Google Scholar
Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagwa ST, et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia. 2013;15:1–10.
Google Scholar
Koshkin VS, Patel VG, Ali A, Bilen MA, Ravindranathan D, Park JJ, et al. PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate Cancer Prostatic Dis. 2022;25:388–96.
Google Scholar
Lowe, Zein K, Hatipoglu J, et al. Association of smoking and cumulative pack-year exposure with COVID-19 outcomes in the cleveland clinic covid-19 registry. JAMA Intern Med. 2021;181:709. https://doi.org/10.1001/jamainternmed.2020.8360.
Google Scholar
Darcey E, Boyle T. Tobacco smoking and survival after a prostate cancer diagnosis: a systematic review and meta-analysis. Cancer Treat Rev. 2018;70:30–40. https://doi.org/10.1016/j.ctrv.2018.07.001.
Google Scholar
García-Cano-Fernández AM, Páez Borda Á, Llanes González L, Luján Galán M. Value of baseline PSA in predicting prostate cancer diagnosis and death. Spanish arm of the European Randomized Study of Screening for Prostate Cancer. Cent Eur J Urol. 2024;77:383–8. https://doi.org/10.5173/ceju.2024.31.R1.
Google Scholar
Rusthoven C, Carlson JA, Waxweiler TV, Yeh N, Raben D, Flaig TW, et al. The prognostic significance of Gleason scores in metastatic prostate cancer. Urol Oncol: Semin Original Investig. 2014;ume 32:707–13.
Google Scholar
Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E. Smoking and prostate cancer survival and recurrence. JAMA. 2011;305:2548–55.
Google Scholar
Joshu CE, Mondul AM, Meinhold CL, Humphreys EB, Han M, Walsh PC, et al. Cigarette smoking and prostate cancer recurrence after prostatectomy. J Natl Cancer Inst. 2011;103:835–8.
Google Scholar
Rieken M, Shariat SF, Kluth LA, Fajkovic H, Rink M, Karakiewicz P, et al. Association of cigarette smoking and smoking cessation with biochemical recurrence of prostate cancer in patients treated with radical prostatectomy. Eur Urol. 2015;68:949–56.
Google Scholar
Zhuang M, Calabrese MF, Liu J, Waddell MB, Nourse A, Hammel M, et al. Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. Mol Cell. 2009;36:39–50. https://doi.org/10.1016/j.molcel.2009.09.022.
Google Scholar
Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44:685–U107. https://doi.org/10.1038/ng.2279.
Google Scholar
Wang ZW, Song YZ, Ye MM, Dai XM, Zhu XQ, Wei WY. The diverse roles of SPOP in prostate cancer and kidney cancer. Nat Rev Urol. 2020;17:339–50
Geng CD, He B, Xu LM, Barbieri CE, Eedunuri VK, Chew SA, et al. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci USA. 2019;116:14386–7.
Google Scholar
Theurillat J-PP, Udeshi ND, Errington WJ, Svinkina T, Baca SC, Pop M, et al. UBIQUITYLOME analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science. 2014;346:85–9. https://doi.org/10.1126/science.1250255.
Google Scholar
Ko J, Meyer AN, Haas M, Donoghue DJ. Characterization of FGFR signaling in prostate cancer stem cells and inhibition via TKI treatment. Oncotarget. 2021;12:22–36.
Google Scholar
Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4:215–66. https://doi.org/10.1002/wdev.176.
Google Scholar
Armstrong K, Ahmad I, Kalna G, Tan SS, Edwards J, Robson CN, et al. Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer. Br J Cancer. 2011;105:1362–9. https://doi.org/10.1038/bjc.2011.367.
Google Scholar
Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, et al. “Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling”.Cancer Cell. 2017;32. https://doi.org/10.1016/j.ccell.2017.09.003.
Hartley A, Galbraith LCA, Shaw R, Tibbo A, Veeratterapillay R, Wilson L, et al. Loss of ARID1A accelerates prostate tumourigenesis with a proliferative collagen-poor phenotype through co-operation with AP1 subunit cFos. Br J Cancer. 2025;132:502–12.
Google Scholar
Davies AH, Beltran H, Zoubeidi A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat Rev Urol. 2018;15:271–86. https://doi.org/10.1038/nrurol.2018.22.
Google Scholar
Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Ben Maad I, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 2012;44:694–8. https://doi.org/10.1038/ng.2256.
Google Scholar
Yamada Y, Beltran H. Clinical and biological features of neuroendocrine prostate cancer. Curr Oncol Rep. 2021;23:15.
Google Scholar
Fang F, Andersen AM, Philibert R, Hancock DB. Epigenetic biomarkers for smoking cessation. Addict Neurosci. 2023;6:100079. https://doi.org/10.1016/j.addicn.2023.100079.
Google Scholar
Von Kroge PR, Bokemeyer F, Ghandili S, Bokemeyer C, Seidel C. The impact of smoking cessation and continuation on recurrence and survival in patients with head and neck cancer: a systematic review of the literature. Oncol Res Treat. 2020;43:549–58. https://doi.org/10.1159/000509427.
Google Scholar
Koshiaris C, Aveyard P, Oke J, Ryan R, Szatkowski L, Stevens R, et al. Smoking cessation and survival in lung, upper aero-digestive tract and Bladder Cancer: Cohort study. Br J Cancer. 2017;117:1224–32. https://doi.org/10.1038/bjc.2017.179.
Google Scholar
Järbur E, Holmberg E, Björk-Eriksson T, Bratt O, Godtman RA. “Associations between socioeconomic factors and PSA testing in a population-based organised testing programme and Routine Healthcare: a register-based study of 50-year-old men”. BMJ Oncol. 2024;3. https://doi.org/10.1136/bmjonc-2024-000400.
Kilpeläinen TP, Talala K, Raitanen J, Taari K, Kujala P, Tammela TLJ, et al. Prostate cancer and socioeconomic status in the finnish randomized study of screening for prostate cancer. Am J Epidemiol. 2016;184:720–31. https://doi.org/10.1093/aje/kww084.
Google Scholar
Hugosson J, Ansrud Godtman R, Carlsson SV, Aus G, Grenabo Bergdahl A, Lodding P, et al. Eighteen-Year follow-up of the göteborg randomized population-based prostate cancer screening trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scand J Urol. 2018;52:27–37. https://doi.org/10.1080/21681805.2017.1411392.
Google Scholar
